Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 25Carcinoma, Non-Small-Cell Lung 6Melanoma 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

pembrolizumab 2Paclitaxel 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sacituzumab govitecan 1pegfilgrastim 1atezolizumab 1Gemcitabine 1Filgrastim 1Epirubicin 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Triple Negative Breast Neoplasms × pembrolizumab × Clear all
NCT03036488 2025-10-29

MK-3475-522

Merck Sharp & Dohme LLC

Phase 3 Completed
1,174 enrolled 1 FDA
Breast

Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 41 charts 1 FDA
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡